By Gwendolyn Wu | July 14, 2026
The high-stakes legal entanglement between venture capital heavyweight Apple Tree Partners (ATP) and the family trust of billionaire Dmitry Rybolovlev, known as Rigmora, has entered a volatile new chapter. A recent ruling from a Cayman Islands court has effectively stripped ATP founder Seth Harrison of his control over the fund, replacing him with independent officers. This development marks a significant shift in a multi-jurisdictional dispute that has already forced the biotech investment firm into Chapter 11 bankruptcy proceedings in the United States.
For years, the partnership between ATP and the Rybolovlev family trust was a cornerstone of biotech innovation, responsible for fueling high-profile startups and transformative research. Now, that relationship has devolved into a bitter contest over governance, fiduciary duty, and the future of billions of dollars in assets.
A Timeline of the Breakdown: From Partnership to Litigation
The friction between ATP and its primary backer did not emerge overnight; it is the culmination of a decade-long evolution in their business relationship.
- 2012: The Rybolovlev family trust enters an agreement to anchor ATP’s investment vehicles, committing up to $1.5 billion to support the firm’s biotech endeavors.
- 2012–2023: ATP utilizes these funds to launch and support a fleet of innovative biotech companies, including Intergalactic Therapeutics, Red Queen Therapeutics, and the high-profile acquisition of Akero Therapeutics.
- 2023: The relationship reaches a breaking point. ATP files a lawsuit against Rigmora in the Delaware Chancery Court, alleging that the investor failed to meet its capital commitments, thereby starving portfolio companies of necessary funding.
- Late 2023: Rigmora launches a counter-offensive in the Cayman Islands, alleging that ATP’s management, under Harrison, has been plagued by mismanagement and that the firm’s core purpose has been compromised.
- December 2023: The Delaware Chancery Court orders Rigmora to pay approximately $97 million to cover budgets for ATP’s portfolio companies, but it explicitly leaves the door open for the Cayman court to decide whether the investor group has sufficient grounds to claim a total loss of confidence in Harrison’s leadership.
- Post-December 2023: ATP initiates Chapter 11 bankruptcy proceedings, a move characterized by Rigmora as a "delay tactic" designed to evade judicial oversight in the Cayman Islands.
- July 2026: The Cayman Islands court rules in favor of Rigmora, ordering the replacement of Harrison with independent officers, setting the stage for a jurisdictional collision between U.S. bankruptcy courts and Cayman judicial authorities.
The Financial Architecture of the Dispute
At the heart of the litigation are the mechanics of venture capital funding and the obligations of limited partners to their general partners. ATP, which reported managing $3.6 billion in assets in recent bankruptcy filings, claims that its operational integrity depends on the fulfillment of long-standing capital commitments.
Conversely, Rigmora’s legal team has argued that the mismanagement of these assets necessitates a fundamental restructuring of the fund’s leadership. With debts totaling approximately $216 million, the stakes for creditors and portfolio companies alike are immense. The $97 million shortfall identified by the Delaware court highlights the liquidity crunch that has forced several of ATP’s startups into a state of operational paralysis.
The impact of this uncertainty is widespread. Biotech startups are notoriously capital-intensive; a disruption in the flow of funding can mean the difference between a breakthrough therapy reaching clinical trials and a company shuttering its laboratories. By tethering its survival to the resolution of this dispute, ATP has effectively made its portfolio companies collateral damage in a boardroom power struggle.
Official Responses: Two Narratives of "Maximized Value"
The public reaction to the Cayman court’s ruling has been predictably polarized, with both sides claiming that their actions are taken in the best interest of the stakeholders and the fund’s long-term health.
In an official statement released Tuesday, Rigmora expressed satisfaction with the court’s decision. "We are convinced that replacing Mr. Harrison with independent officers is in the best interest of the fund and will result in the maximization of the fund’s value," the statement read. Rigmora’s legal representatives have already petitioned the U.S. bankruptcy court to recognize the authority of the newly appointed independent directors, effectively aiming to install their own governance team within the bankruptcy process.
ATP, however, remains defiant. In its response, the firm emphasized that the Cayman Islands ruling has not yet been recognized by U.S. authorities. ATP asserts that the Delaware bankruptcy court retains exclusive jurisdiction over the reorganization plan.
"The Delaware bankruptcy court has repeatedly reserved for itself solely to decide the go-forward plan," a spokesperson for the firm stated. Under the current proposal submitted by Harrison, the firm is seeking to secure funding for its portfolio companies for the remainder of the year. Notably, that plan involves a bidding process in which Harrison himself may participate to acquire certain assets, a move critics argue could create a conflict of interest while supporters might view as a necessary step to salvage the firm’s intellectual property.
Implications for the Biotech Venture Ecosystem
The case of ATP versus Rigmora serves as a cautionary tale for the biotech venture capital industry, highlighting the fragility of long-term partnerships when capital demands meet governance crises.
The Jurisdictional Tug-of-War
One of the most significant implications of this case is the ongoing conflict between U.S. bankruptcy laws and international corporate oversight. If the Delaware court refuses to acknowledge the authority of the Cayman-appointed directors, it could set a precedent for how international venture funds are managed during insolvency. This creates an environment of extreme uncertainty for the portfolio companies, which are currently caught in a "no-man’s land" regarding who actually holds the keys to their treasury.
The Vulnerability of Portfolio Companies
Startups backed by ATP are now forced to operate under the shadow of a parent company that is embroiled in litigation. For employees and researchers, this translates to frozen hiring, delayed clinical milestones, and difficulty in attracting external investors or strategic partners. The market perception of these companies—previously viewed as high-potential ventures—is now being colored by the legal drama of their primary backer.
The Future of "Active" Venture Management
ATP’s model—which involves heavy, hands-on management and the creation of companies from the ground up—requires a high degree of trust between the general partner and the limited partner. As this case progresses, other institutional investors may look toward more passive investment strategies or demand more stringent governance and oversight mechanisms to prevent similar escalations. The "Harrison model" of absolute control, while successful in the early days of ATP, is now under intense scrutiny, suggesting that the era of the "founder-as-king" in venture capital may be facing a reckoning.
Conclusion: A Path Forward or a Protracted War?
As the summer of 2026 unfolds, the industry is watching closely to see whether the Delaware bankruptcy court will grant recognition to the new Cayman-appointed leadership. If the court sides with Rigmora, the transition could lead to a rapid liquidation or restructuring of ATP’s assets. If it sides with Harrison, the battle could drag on for months, if not years, through the appellate courts.
For the biotech sector, the tragedy of this dispute is that while legal maneuvers dominate the headlines, the core mission—the development of life-saving medicines—remains in limbo. Whether through a negotiated settlement or a court-ordered restructuring, the primary objective must eventually return to the stability of the science. Until then, ATP stands as a stark example of how, in the high-stakes world of biotech finance, the breakdown of a relationship can be just as destructive as the failure of the science itself.
About the Author
